News and Press Releases

Prosarix contributes to Prolysis' discovery of novel antibacterials, now published in Science

Cambridge, UK, September 24th 2008 — Prolysis Ltd, an antibacterial drug discovery company based in Oxford, UK, has published the discovery of a new class of antibacterials in the the prestigious international journal, Science. As a partner to Prolysis, Prosarix carried out the computational chemistry component of this work, which utilised elements of its ProtoDiscovery™ platform.

The paper describes the discovery of a new and efficacious bactericidal class of antibacterials that kill staphylococci by inhibiting their cell division process. The success of these inhibitors against a novel target site and their potential to treat drug-resistant infections is a significant event in this therapeutic area.

An inhibitor of FtsZ with potent and selective anti-staphylococcal activity
Haydon, DJ1, Stokes, NR1, Ure, R1, Galbraith, G1, Bennett, JM1, Brown, DR1, Baker, PJ2, Barynin, VV2, Rice, DW2, Sedelnikova, SE2, Heal, JR3, Sheridan, JM3, Aiwale, ST4, Chauhan, PK4, Srivastava, P4, Taneja, A4, Collins, I1, Errington, J1,5 and Czaplewski, LG1

1 Prolysis Ltd, Begbroke Science Park, Oxfordshire, OX5 1PF, United Kingdom.
2 Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield,
  S10 2TN, United Kingdom.
3 Prosarix Ltd, Newton Hall, Cambridge, CB22 7ZE, United Kingdom.
4 Jubilant Chemsys Ltd, B-34, Sector-58, Noida - 201301, India.
5 Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Newcastle
  University, Newcastle upon Tyne, NE2 4HH, United Kingdom.

Science (2008) 321:1673-1675


©Prosarix 2007-2020

℅ RxCelerate Ltd, Moneta B280, Babraham Research Park, Cambridge, CB22 3AT ¦ +44 (0)1223 839557 ¦ ¦ legal